Hansa Biopharma (HGEN) trial results presentation at ATC June

AI Summary

Hansa Biopharma's (HGEN) trial results will be presented at the Annual Transplantation Congress (ATC) in June. This event is significant as it could provide insights into the effectiveness of their therapies. The outcomes of these trials may influence investor sentiment and stock performance. Future data from the meeting could impact market evaluations of Hansa Biopharma's therapies and their potential adoption.